
|Articles|April 1, 2003
Should a prostaglandin agent be used as initial monotherapy?
Not long after topical timolol was introduced in 1978, it became one of the most widely prescribed glaucoma medications in the world. Although timolol is considered to be the most significant therapeutic advance in the medical treatment of glaucoma in the 20th century, the 1994 introduction of prostaglandin analogs for glaucoma treatment in Japan marked the end of timolol's domination.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
STAAR postpones Alcon merger vote, Broadwood calls for removal of board members
2
FDA issues Complete Response Letter to Sydnexis for SYD-101 pediatric myopia treatment
3
Novel therapy for incision-free keratoconus: Q&A with Gloria B. Chiu, OD, FAAO, FSLS
4
Nanoscope Therapeutics releases positive 3-year follow-up data from REMAIN study
5
 
 
















































.png)


